MSL
BPMC

Mackay Shields LLC’s Blueprint Medicines BPMC Stock Holding History

Mackay Shields LLC’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-18,453
Closed -$1.79M – 791
2021
Q1 		$1.79M Sell
18,453
-10,669
-37% -$1.07M 0.01% 816
2020
Q4 		$3.27M Sell
29,122
-4,300
-13% -$453K 0.02% 633
2020
Q3 		$3.1M Sell
33,422
-1,600
-5% -$123K 0.02% 600
2020
Q2 		$2.73M Sell
35,022
-3,400
-9% -$230K 0.02% 623
2020
Q1 		$2.25M Buy
38,422
+6,600
+21% +$425K 0.02% 621
2019
Q4 		$2.55M Sell
31,822
-4,800
-13% -$359K 0.02% 773
2019
Q3 		$2.69M Buy
36,622
+2,200
+6% +$190K 0.02% 773
2019
Q2 		$3.25M Buy
34,422
+21,869
+174% +$1.8M 0.02% 723
2019
Q1 		$1M Sell
12,553
-300
-2% -$22.2K 0.01% 1000
2018
Q4 		$693K Sell
12,853
-1,347
-9% -$81.9K 0.01% 1053
2018
Q3 		$1.11M Sell
14,200
-100
-0.7% -$6.95K 0.01% 854
2018
Q2 		$908K Hold
14,300
– – 0.01% 979
2018
Q1 		$1.31M Buy
+14,300
New +$1.23M 0.01% 913

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Mackay Shields LLC's BPMC Position: Q2 2021 in Review

Mackay Shields LLC sold out of Blueprint Medicines (BPMC) in Q2 2021, closing a stake of 18,453 shares — an estimated $1.79M sold.

Mackay Shields LLC first reported a position in BPMC in Q1 2018 and held it in 13 quarters. The position peaked at $3.27M in Q4 2020. 281 funds tracked by Wall St. Rank hold BPMC as of Q2 2021.

  • Mackay Shields LLC reported no remaining Blueprint Medicines position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 18,453 Blueprint Medicines shares in Q2 2021, an estimated $1.79M.
  • Mackay Shields LLC first reported a position in Blueprint Medicines in Q1 2018 and held it in 13 quarters.
  • Mackay Shields LLC's Blueprint Medicines position peaked at $3.27M in Q4 2020.
  • 281 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.